Education
About Us
Working with TipRanks
Follow Us
Doximity (DOCS)
NYSE:DOCS
DOCS Stock Chart & Stats
$24.53
-$0.33(-0.59%)
At close: 4:00 PM EST
$24.53
-$0.33(-0.59%)
Day’s Range― - ―
52-Week Range$23.53 - $76.51
Previous CloseN/A
Volume296.07K
Average Volume (3M)4.10M
Market Cap
$4.53B
Enterprise Value$4.55B
Total Cash (Recent Filing)$735.13M
Total Debt (Recent Filing)$10.69M
Price to Earnings (P/E)20.6
Beta1.50
Next Earnings
May 19, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding133,811,550
10 Day Avg. Volume3,291,638
30 Day Avg. Volume4,098,904
Financial Highlights & Ratios
PEG Ratio0.92
Price to Book (P/B)10.01
Price to Sales (P/S)19.01
P/FCF Ratio40.65
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue7.14
Enterprise Value/Gross Profit7.95
Enterprise Value/Ebitda16.71
Forecast
1Y Price Target
$41.13Price Target Upside67.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)1.55
Revenue Forecast (FY)$643.33M
Bulls Say, Bears Say
Bulls Say
AI Adoption And Clinical TrustExtensive clinical review and adoption of the company's AI suite by leading physicians and major health systems builds institutional trust and creates a difficult-to-replicate competitive moat that supports future monetization.
Pharmaceutical Bookings MomentumA pickup to record pharmaceutical bookings and client approvals signals accelerating demand for doctor-targeted marketing, which can help revenue recovery as marketing spend normalizes.
Share Repurchase And Balance SheetA large board-approved share repurchase authorization combined with a strong cash balance and robust free cash flow provides downside support and enhances shareholder value through buybacks.
Bears Say
AI Monetization RampMonetization of embedded AI features is likely to ramp slowly, requiring substantial sales effort to drive discovery and adoption inside health system workflows and delaying revenue realization.
Infrastructure Costs And Margin PressureRising AI infrastructure and usage costs without immediate revenue offsets will compress margins and weigh on reported profitability until monetization scales.
Policy Uncertainty And Pharma BudgetsHealthcare policy uncertainty is causing pharmaceutical clients to delay pricing agreements and contract signings, reducing near-term revenue visibility and increasing execution risk.
Doximity News
DOCS FAQ
What was Doximity’s price range in the past 12 months?
Doximity lowest stock price was $23.53 and its highest was $76.51 in the past 12 months.
What is Doximity’s market cap?
Doximity’s market cap is $4.53B.
When is Doximity’s upcoming earnings report date?
Doximity’s upcoming earnings report date is May 19, 2026 which is in 79 days.
How were Doximity’s earnings last quarter?
Doximity released its earnings results on Feb 05, 2026. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.447 by $0.013.
Is Doximity overvalued?
According to Wall Street analysts Doximity’s price is currently Undervalued.
Does Doximity pay dividends?
Doximity does not currently pay dividends.
What is Doximity’s EPS estimate?
Doximity’s EPS estimate is 0.28.
How many shares outstanding does Doximity have?
Doximity has 133,811,550 shares outstanding.
What happened to Doximity’s price movement after its last earnings report?
Doximity reported an EPS of $0.46 in its last earnings report, beating expectations of $0.447. Following the earnings report the stock price went down -16.777%.
Which hedge fund is a major shareholder of Doximity?
Currently, no hedge funds are holding shares in DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Doximity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.13 (67.67% Upside)
$41.13 (67.67% Upside)
Blogger Sentiment
Bullish
DOCS Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 608.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.97%
12-Months-Change
Fundamentals
Return on Equity
23.82%
Trailing 12-Months
Asset Growth
-1.29%
Trailing 12-Months
Company Description
Doximity
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
DOCS Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial health: solid Q3 revenue (+10% YoY) and high absolute profitability (Q3 adjusted EBITDA $111.4M, 60% margin), impressive platform scale and rapid AI adoption (300K+ prescribers, 100+ health systems, 10K peer reviewers), and a robust balance sheet with active buybacks. Near-term headwinds center on timing and policy-driven customer budget uncertainty (MFN), increased AI infrastructure costs pressuring gross margin, and the fact that AI monetization is not yet reflected in guidance. Overall, the positive execution, cash generation, and AI traction outweigh the short-term headwinds and investment-related margin pressure.View all DOCS earnings summariesDOCS Revenue Breakdown
93.00% Subscription
7.00% Other
DOCS Stock 12 Month Forecast
Average Price Target
$41.13
▲(67.67% Upside)
Technical Analysis
Omnicell
―
Evolent Health
―
Teladoc
―
Definitive Healthcare Corp
―
Tempus AI, Inc. Class A
―
Ownership Overview
2.50% Insiders
32.63% Mutual Funds
18.52% Other Institutional Investors
26.02% Public Companies and
Individual Investors